Loading clinical trials...

Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study

NCT04643327•The University of Queensland

View on ClinicalTrials.gov

Summary

The present study is a proof-of-concept clinical trial to test the efficacy of low doses of a repurposed anti-epileptic drug (levetiracetam) in treating memory problems in Parkinson's disease (PD). Neuroimaging techniques will be used to determine the effect of the drug on specific brain regions (hippocampal subfields). Finally, baseline brain activity of PD patients with memory problems will be compared to PD patients without memory problems and healthy older adults to determine if activity in specific brain regions (hippocampal subfields) can be used to predict memory problems in PD. This information will be useful for future clinical trials to target drugs to these brain regions.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Parkinson's Disease patients with amnestic Mild Cognitive Impairment
•Parkinson's Disease patients with no memory impairment
•Healthy volunteers
•All participants must be eligible to take MRI scans

Exclusion Criteria

•Dementia
•Contraindication to having MRI
•Bipolar disorder, Schizophrenia, Alcohol or substance abuse
•Major depression
•Suicidal Ideation
•Difficulty complying with protocol requirements
•Significant non-PD neurological disease
•Vascular dementia
•Sensitivity to levetiracetam
•Use of anticonvulsant medications
+4 more criteria

Locations (1)

University of Queensland Centre for Clinical Research

Brisbane, Queensland, Australia

Key Dates

Start Date

February 9, 2021

Primary Completion Date

January 1, 2025

Completion Date

December 1, 2025

Last Updated

September 25, 2024

Enrollment

ESTIMATED participants

Conditions

Parkinson DiseaseMild Cognitive ImpairmentMemory Impairment

Interventions

Levetiracetam

DRUG

Placebo

DRUG

Sense4Safety Intervention

NCT07220668

Mild Cognitive Impairment

View study

RECRUITINGNA

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

NCT06692920

Parkinson Disease

View study

RECRUITINGPHASE1

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 25, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

Inclusion Criteria

Exclusion Criteria

Sense4Safety Intervention

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Montelukast in Parkinson Disease

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment